Zobrazeno 1 - 10
of 836
pro vyhledávání: '"Suresh S. Ramalingam"'
Autor:
Zhen Chen, Karin A. Vallega, Vijay K. Boda, Zihan Quan, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S. Ramalingam, Wei Li, Shi‐Yong Sun
Publikováno v:
Advanced Science, Vol 11, Iss 35, Pp n/a-n/a (2024)
Abstract There is an urgent need to fully understand the biology of third generation EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs), particularly osimertinib, and to develop mechanism‐driven strategies to manage their acquired resistance. Transien
Externí odkaz:
https://doaj.org/article/724fd6fccbf0485f8840bc5a1b713315
Autor:
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d
Externí odkaz:
https://doaj.org/article/50d39c846b474baea88547c6b345e6aa
Autor:
Madhusmita Behera, PhD, Renjian Jiang, MS, Zhonglu Huang, MS, Becky Bunn, MS, Murry W. Wynes, PhD, Jeffrey Switchenko, PhD, Giorgio V. Scagliotti, MD, Chandra P. Belani, MD, Suresh S. Ramalingam, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 6, Pp 100592- (2024)
Introduction: EGFR exon 20 insertion (ex20ins) mutations account for approximately 10% of EGFR mutations in lung adenocarcinoma. Patients with ex20ins mutation do not respond to standard EGFR tyrosine kinase inhibitor therapy. In this work, we analyz
Externí odkaz:
https://doaj.org/article/f92ad290cb7e478fb92426609abe2a43
Autor:
Sarah A. Westergaard, Manali Rupji, Lauren E. Franklin, Madhusmita Behera, Suresh S. Ramalingam, Kristin A. Higgins
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7339-7347 (2023)
Abstract Introduction Tobacco cessation is a critical but challenging intervention for cancer patients. Our National Cancer Institute‐designated Comprehensive Cancer Center instituted a tobacco cessation program in 2019. This manuscript reports on
Externí odkaz:
https://doaj.org/article/a2b1f08bf59b49508a2109caf908f457
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimer
Externí odkaz:
https://doaj.org/article/44b83896764b4d85bc01ecb3c4630dd4
Autor:
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
In the phase III AURA3 study (NCT02151981), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib prolonged progression-free survival versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCL
Externí odkaz:
https://doaj.org/article/97023c9e42e0450eab3688b9d4689761
Autor:
Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100546- (2023)
Introduction: Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction. However, the impact of dose reductions on
Externí odkaz:
https://doaj.org/article/4a17b716e5554aaa9e42589db4af6e82
Autor:
William A. Stokes, Madhusmita Behera, Renjian Jiang, David A. Gutman, Zhonglu Huang, Abigail Burns, Nikhil T. Sebastian, Vidula Sukhatme, Michael C. Lowe, Suresh S. Ramalingam, Vikas P. Sukhatme, Drew Moghanaki
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 358-367 (2023)
Abstract Background Peroxisome proliferator‐activated receptor agonists such as fibrates restore oxidative metabolism in cytotoxic T‐lymphocytes, thereby enhancing response to immune checkpoint inhibitors (ICI) in preclinical models. However, the
Externí odkaz:
https://doaj.org/article/38bd7141aeb7447eb83d8b4d4ffa906d
Autor:
Mayar Allam, Thomas Hu, Jeongjin Lee, Jeffrey Aldrich, Sunil S. Badve, Yesim Gökmen-Polar, Manali Bhave, Suresh S. Ramalingam, Frank Schneider, Ahmet F. Coskun
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-21 (2022)
Abstract The Immunoscore is a method to quantify the immune cell infiltration within cancers to predict the disease prognosis. Previous immune profiling approaches relied on limited immune markers to establish patients’ tumor immunity. However, imm
Externí odkaz:
https://doaj.org/article/9e5070068683451ebbd1a83b5eb66b7b
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/9ac77df433144c60bb72e35db443b3df